复方阿胶浆对化疗所致小细胞肺癌骨髓抑制的影响
Efficacy of compound e-jiao slurry on marrow suppression of small-cell lung cancer after chemotherapy

DOI: 10.6040/j.issn.1671-7554.0.2017.771

Keywords: 化疗,小细胞肺癌,复方阿胶浆,骨髓抑制,
Compound e-jiao slurry,Chemotherapy,Small-cell lung cancer,Marrow suppression

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Li Y, He H, Yang L, et al. Therapeutic effect of Colla corii asini on improving anemia and hemoglobin compositions in pregnant women with thalassemia[J]. Int J Hematol, 2016, 104(5): 559-565.
[2]	管燕,李艳,王丽杰,等.恶性肿瘤化疗后骨髓抑制患者复方阿胶浆应用观察[J].山东医药, 2013, 53(47): 51-52.
[3]	Wang D, Ru W, Xu Y, et al. Chemical constituents and bioactivities of Colla corii asini[J]. Drug Discov Ther, 2014, 8(5): 201-207.
[4]	徐振晔,朱晏伟,周卫东,等.双黄升白冲剂与粒-巨噬细胞集落刺激因子治疗肺癌化疗骨髓抑制44例临床研究[J].中医杂志, 2003, 44(12): 919-921.
[5]	Wu H, Yang F, Cui S, et al. Hematopoietic effect of fractions from the enzyme-digested colla corii asini on mice with 5-fluorouracil induced anemia[J]. Am J Chin Med, 2007, 35(5): 853-866.
[6]	陈慧慧,尤金花,田守生,等.复方阿胶浆药理及临床研究概况[J].中国中药杂志, 2012, 37(20): 3021-3023. CHEN Huihui, YOU Jinhua, TIAN Shousheng, et al. Overview of pharmacological and clinical study on compound Ejiao Jiang[J]. China Journal of Chinese Materia Medica, 2012, 37(20): 3021-3023.
[7]	Wu H, Ren C, Yang F, et al. Extraction and identification of collagen-derived peptides with hematopoietic activity from Colla Corii Asini[J]. J Ethnopharmacol, 2016, 182: 129-136.
[8]	王慧娟,闫相涛,路平,等.伊立替康联合顺铂与依托泊苷联合顺铂方案一线治疗广泛期小细胞肺癌的多中心临床研究结果[J].中国癌症杂志, 2011, 21(10): 783-788. WANG Huijuan, YAN Xiangtao, LU Ping, et al. Irinotecan plus cisplatin versus etoposide plus cisplatin as the first-line therapy for extensive-disease small cell lung cancer: preliminary results of a multicenter clinical study[J]. China Oncology, 2011, 21(10):783-788.
[9]	尹良伟,马海英,王颖,等.顺铂联合依托泊苷或伊立替康及拓扑替康一线治疗小细胞肺癌的比较研究[J].中华肿瘤防治杂志, 2013, 20(10): 782-785. YIN Liangwei, MA Haiying, WANG Ying, et al. Cisplation combined with etoposide irinotecan and topotecan respectively for patients with small cell lung cancer as first-line treatment [J]. Chin J Cancer Prev Treat, 2013, 20(10): 782-785.
[10]	王中奇,邓海滨,吴继,等.双黄升白颗粒治疗肺癌化疗后骨髓抑制的临床研究[J].上海中医药杂志, 2013, 47(6): 35-37. WANG Zhongqi, DENG Haibin, WU Ji, et al. Clinical research of “Shuanghuang Shengbai Granule” on arrest of bone marrow in patients with lung cancer after chemotherapy[J]. Shanghai Journal of Traditional Chinese Medicine, 2013, 47(6): 35-37.
[11]	韩海帆,张路,张淹,等. NIRS法快速测定复方阿胶浆中总黄酮、总皂苷和可溶性固形物[J].中草药, 2013, 44(17): 2397-2403. HAN Haifan, ZHANG Lu, ZHANG Yan, et al. Rapid determination of total flavonoids, total saponins, and soluble solid content in Fufang Ejiao Syrup by NIRS[J]. Chinese Traditional and Herbal Drugs, 2013, 44(17): 2397-2403.
[12]	Liu M, Tan H, Zhang X, et al. Hematopoietic effects and mechanisms of Fufang ejiao jiang on radiotherapy and chemotherapy-induced myelosuppressed mice[J]. J Ethnopharmacol, 2014, 152(3): 575-584.
[13]	Wang D, Liu M, Cao J, et al. Effect of Colla corii asini( E’jiao)on D-galactose induced aging mice[J]. Biol Pharm Bull, 2012, 35(12): 2128-2132.
[14]	杨长良,马丽霞,孙双燕,等.依托泊苷联合顺铂治疗有效患者继续原方案不同时间维持治疗小细胞肺癌患者的疗效和不良反应[J].中华肿瘤杂志, 2016, 38(6): 454-459. YANG Changliang, MA Lixia, SUN shuangyan, et al. Efficiency and adverse effects of the effective therapy applying etoposide + cisplatin and its subsequent maintenance therapy with different durations in patients with small cell lung cancer[J]. Chin J Oncol, 2016, 38(6): 454-459.
[15]	郑筱祥,杨勇,叶剑锋,等.东阿阿胶的升白作用及机制研究[J].中国现代应用药学, 2005, 22(2): 102-105. ZHENG Xiaoxiang, YANG Yong, YE Jianfeng, et al. The mechanism of Donkey-hide gelatin in increasing leukocyte [J]. The Chinese Journal of Modern Applied Pharmacy, 2005, 22(2): 102-105.
[16]	游捷,单孟俊,赵慧,等.中西医结合治疗91例老年晚期非小细胞肺癌疗效观察[J].中国中西医结合杂志, 2012, 32(6): 774-778. YOU Jie, SHAN Mengjun, ZHAO Hui, et al. Clinical study of integrative treatment for ninety-one elderly patients with advanced non-small cell lung cancer[J]. CJITWM, 2012, 32(6): 774-778.
[17]	黄超,黎丽群,吴耀忠,等.芪胶升白胶囊防治恶性肿瘤化疗后骨髓抑制疗效的Meta分析[J].山东医药, 2015, 55(24): 66-68.
[18]	敖曼,连相尧,刘承一,等.参芪扶正注射液对肺癌化疗患者造血功能和免疫功能的影响[J].山东医药, 2012, 52(3): 60-61.
[19]	段哲萍,于新江,吕艳玲,等.复方苦参注射液对非小细胞肺癌放疗患者放射性肺损伤及骨髓抑制的防治作用及机制[J].山东医药, 2016, 56(32): 81-83.
[20]	邓艳,柯晴,毛艳.参芪扶正注射液对晚期非小细胞肺癌化疗患者造血和免疫功能的干预作用[J].中国老年学杂志, 2015, 35(21): 6142-6144.
[21]	李伟伟,崔艳慧,蔡卫梅. 肺癌患者化疗期间发生感染的相关危险因素分析[J].中华医院感染学杂志, 2013, 23(6): 1277-1279. LI Weiwei, CUI Yanhui, CAI Weimei. Risk factors for infections in lung cancer patients during chemotherapy[J]. Chin J Nosocomiol, 2013, 23(10): 2316-2318.
[22]	罗洁,李爱武,吴凤英,等. NIP与EP方案一线治疗167例晚期复合性小细胞肺癌的回顾性分析[J].肿瘤, 2012, 32(3): 194-198. LUO Jie, LI Aiwu, WU Fengying, et al. Navelbine-ifosfamide-cisplatin versus etoposide-cisplatin as the first-line treatment of advanced combined small-cell lung cancer: restrospective analysis of 167 cases [J]. Tumor, 2012, 32(3): 194-198.
[23]	黄慧强,王潇潇. 重组人粒-巨噬细胞集落刺激因子临床新应用进展[J].中华血液学杂志, 2012, 33(5): 429-431.
[24]	孙广玉,王淑燕,宋相孔,等. 肺癌患者放化疗后肺部感染的相关因素分析[J].中华医院感染学杂志, 2014, 24(18): 4488-4490. SUN Guangyu, WANG Shuyan, SONG Xiangkong, et al. Related factors for pulmonary infections in lung cancer patients after chemoradiotherapy[J]. Chin J Nosocomiol, 2014, 24(18): 4488-4490.
[25]	李常青. 肿瘤化疗医院感染的相关因素分析及防范措施探讨[J].中华医院感染学杂志, 2013, 23(10): 2316-2318. LI Changqing. Related factors of nosocomial infections in tumor patients undergoing chemotherapy and exploration of prevention measures[J]. Chin J Nosocomiol, 2013, 23(10): 2316-2318.

Full-Text